BCR-ABL1 compound mutants: prevalence, spectrum and correlation with tyrosine kinase inhibitor resistance in a consecutive series of Philadelphia chromosome-positive leukemia patients analyzed by NGS
- 1 July 2021
- journal article
- letter
- Published by Springer Science and Business Media LLC in Leukemia
- Vol. 35 (7), 2102-2107
- https://doi.org/10.1038/s41375-020-01098-w
Abstract
No abstract availableThis publication has 16 references indexed in Scilit:
- Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML studyBlood, 2020
- BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinibHaematologica, 2018
- Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2016
- Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patientsBlood, 2016
- BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive LeukemiaCancer Cell, 2014
- Molecular dynamics reveal BCR-ABL1 polymutants as a unique mechanism of resistance to PAN-BCR-ABL1 kinase inhibitor therapyProceedings of the National Academy of Sciences of the United States of America, 2014
- European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013Blood, 2013
- BCR-ABL1 compound mutations in tyrosine kinase inhibitor–resistant CML: frequency and clonal relationshipsBlood, 2013
- BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNetBlood, 2011
- Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potencyJCI Insight, 2007